Dr. Sharron Gargosky is a clinical, scientific, and regulatory professional with more than 25 years of experience in global clinical development and operations. Her focus is in the field of pharmaceutical and biologic development having managed international programs from early research phase through the U.S. Ophan Drug and Accelerated Food & Drug Administration approval process. Previously, she served as the Clinical Development Officer for Alloplex Biotherapeutics, as well as providing consulting to support strategic decisions and development plans and business development opportunities for clients in the IndoPac region. 

Most recently Dr. Gargosky was Chief Clinical and Regulatory Officer for OncoSec, leading all areas of development program for its intratumoral immunotherapy to more broadly address anti-PD-1 resistant cancers. She also has served in positions of increasing clinical and scientific responsibility at biopharmaceutical companies including: Pharmacia, Medicis/Ucyclyd, Hyperion Therapeutics and Prima Biomed. Dr. Gargosky received her PhD from the University of Adelaide, Australia and completed her postdoctoral fellowship at Stanford University.